Check 35,000+ stocks against 26 valuation models and 37 quality factors

Cross Country Healthcare Inc (CCRN) fair value: what the stock is really worth

As of Jul 24, 2026: fair value of Cross Country Healthcare Inc $15.21, price $13.25, upside +14.8%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US2274831047

Some data Sep 24, 2026

Cross Country Healthcare Inc

CCRN · US

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value $15.21 · Undervalued (+14.8%)

✓Quality 61/100

!Weak Growth (revenue 5y +4.7 %/yr)

!Loss-making · -9.8% net margin (TTM)

✓Low debt · generates free cash flow

!Trails peers (5/13)

!Narrow moat 13/100

!Evidence only medium, so the estimate is less certain

26 models, one by oneBear $10.19 to bull $21.23 Growth analysisrevenue history, year by year Quality 61/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Cross Country Healthcare Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $7.53 – $38.10 · fair‑value band $10.19 – $21.23 · the $13.25 price screens below the $15.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Cross Country Healthcare in your weekly email

Every Wednesday you see whether Cross Country Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance; vendor neutral and managed services programs; and education healthcare, caregiver services, and outsourcing services. This segment offers staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term assignments, as well as workforce solutions, including MSP, VMS, RPO, project management, and other outsourcing and consultative services. It also provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. The company serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, correctional facilities, PACE programs, physician practice groups, and other healthcare providers. The Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments. This segment serves various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.

Stock analysis

Cross Country Healthcare Inc (CCRN) currently trades at $13.25, while our model-based Fair Value estimate is $15.21, implying the stock looks roughly 12.9% undervalued today.

Valuation

Bull case: the Growth DCF group reads highest at a median of $14.13 per share, and 6 of the 10 models we run sit above the $13.25 price.

Bear case: the Multiples group reads lowest at $4.54, and 4 of the 10 models stay below the price. Evidence for this calculation is medium.

Scenario range: $10.19 (bear) to $21.23 (bull), the price of $13.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Cross Country Healthcare Inc reported revenue of $1.1B in FY2025 versus $1.7B in FY2021, a compound −11.0%/yr. Reported net income was −$94.9M in FY2025.

Key figures

Market cap $429M · P/S ratio 0.42 · EPS (TTM) $−3.05 · Net margin −9.0% · Return on equity −27.0% · Return on assets (EBIT) 12.1% · Operating margin −0.8% · Revenue (TTM) $1.0B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 7% below its 52-week high and 76% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 15%, CCRN screens cheaper than that median.

Fair Value models

Bear $10.19 Fair Value $15.21 Bull $21.23

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $10.26 $14.31 $19.35 79

Growth DCF $10.45 $14.13 $18.49 77

5Y EBITDA Exit $5.74 $7.88 $10.17 74

All 10 models by family

DCF Models

FCF DCF $10.26 $14.31 $19.35 79

5Y Revenue Exit $9.71 $14.95 $21.36 70

5Y EBITDA Exit $5.74 $7.88 $10.17 74

10Y Revenue Exit $9.56 $14.00 $19.43 65

10Y EBITDA Exit $7.56 $9.63 $11.97 68

Multiples

EV/EBITDA $3.10 $4.54 $5.98 67

EV/Revenue $10.05 $14.89 $19.73 53

Asset-Based

NCAV (Graham) $5.00 $6.69 $9.99 54

Growth DCF

Growth DCF $10.45 $14.13 $18.49 77

Rev-Margin DCF $9.71 $15.11 $20.93 70

Open the full fair value analysis →

Notify me when CCRN reaches fair value

Put CCRN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 61/100

Of which business quality 63 · Market factors (momentum, volatility) 65

Profitability 36

Margins and returns on capital today

Quality Growth 23

Are margins and returns improving?

Cashflow 46

Earnings quality: real cash, not paper profit

Fin. Strength 89

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 57

Calm price path (market factor)

Momentum 73

Price trend over the last 3–12 months (market factor)

52W Momentum 59

Distance to the 52-week high (market factor)

Net Issuance 100

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−21.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−27.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.7%

Start year 2020 (pandemic). Over 10 years: +3.2% a year

Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−1.1% (2020) → −0.3% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

Price in line with expectations

The price assumes less growth than the company has delivered so far and about what analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+0.2%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+1.5%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −2.1% a year for the price and −0.8% for the forecasts.

Forecast 2026 (sales)−6.7%

Forecast 2027 (sales)+4.1%

Projected 2028 (sales)+3.8%

Projected 2029 (sales)+3.6%

Projected 2030 (sales)+3.3%

Watch CCRN, get fair value alerts →

Compare Cross Country Healthcare Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 5/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 61 · Above median

Fair Value upside +14.8% · Above median

Profitability

Return on assets −0.1% · Bottom 25%

Net margin (TTM) −9.8% · Bottom 25%

Operating margin (TTM) −0.8% · Bottom 25%

Growth and dividend

Revenue growth −17.8% · Bottom 25%

Balance sheet

Debt / equity 0.46× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.33× · Cheaper than median

P/S (TTM) 0.43× · Cheapest 25%

P/FCF 10.7× · Cheaper than median

EV/EBITDA 33.3× · Priciest 25%

PEG 12.54× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)53 · sector 34

FUTURE (revenue growth)0 · sector 26

PAST (return on equity)0 · sector 31

HEALTH (low debt)77 · sector 90

DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc HCA	$431.63	$597.97	+39%
Fresenius SE FRE	€43.64	€34.49	−21%
Dr. Sulaiman Al Habib Medical Services Group 4013	225.00 SAR	109.45 SAR	−51%
Tenet Healthcare Corporation THC	$257.93	$274.35	+6%
IHH Healthcare Berhad, an investment holding company, 5225	8.03 MYR	4.87 MYR	−39%
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,889	₹2,908	−67%
Encompass Health Corporation EHC	$123.47	$94.47	−23%
Fresenius Medical Care AG FMS	$22.27	$45.84	+106%
DaVita Inc DVA	$178.07	$215.81	+21%
Aier Eye Hospital Group 300015	¥7.91	¥10.86	+37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cross Country Healthcare Inc · Fair Value
$15.21 +13%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CCRN" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Cross Country Healthcare Inc · Fair Value</span><br><b style="font-size:20px">$15.21</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+13%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Cross Country Healthcare Inc Fair Value". https://www.fairvalue-calculator.com/stock/CCRN

Frequently asked questions

Is Cross Country Healthcare Inc (CCRN) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $15.21 versus the last price from Jul 24, 2026 of $13.25, about +15% upside (undervalued).

What is the fair value of CCRN?

Our model-based fair value for Cross Country Healthcare Inc is $15.21 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 24, 2026): $13.25.

What is the quality score of CCRN?

Cross Country Healthcare Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Cross Country Healthcare Inc (CCRN)?

Our model-based price target is the fair value of $15.21 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $10.19, optimistic scenario $21.23. It is a calculation from audited fundamentals, not an analyst target.

What is the Cross Country Healthcare Inc stock forecast for 2026?

Our models put fair value at $15.21, about +15% upside versus the last price from Jul 24, 2026 of $13.25 (undervalued). Cautious scenario $10.19, optimistic scenario $21.23. The calculation is refreshed regularly with new filings.

What is the revenue of Cross Country Healthcare Inc (CCRN)?

Cross Country Healthcare Inc reported trailing-twelve-month revenue of about $1.0B (latest available figure, as of Sep 24, 2026).

What growth is priced into Cross Country Healthcare Inc (CCRN)?

For today's price to be fair in a discounted-cash-flow model, Cross Country Healthcare Inc would have to grow free cash flow by +0.2 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.7 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of CCRN use?

Our models discount Cross Country Healthcare Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.45, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cross Country Healthcare Inc that is +0.2 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.

How much growth has Cross Country Healthcare Inc (CCRN) delivered so far?

Over the past 5 years revenue at Cross Country Healthcare Inc grew +4.7 % a year. The price currently implies +0.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Cross Country Healthcare Inc (CCRN) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Cross Country Healthcare Inc (+0.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Cross Country Healthcare Inc (CCRN)?

The free-cash-flow yield on the price is 9.34 %: that much free cash flow Cross Country Healthcare Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Cross Country Healthcare Inc (CCRN)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cross Country Healthcare Inc it is $15.21 per share (as of Sep 24, 2026), against a price of $13.25. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).

Is Cross Country Healthcare Inc stock overvalued or undervalued in 2026?

As of Sep 24, 2026, CCRN trades below its calculated fair value: price $13.25, fair value $15.21, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CCRN?

No. The price is what the market pays today ($13.25); the fair value is what the company's own numbers justify ($15.21). For Cross Country Healthcare Inc the two are $1.96 per share apart. That gap is exactly why we show both numbers side by side.

How much is Cross Country Healthcare Inc worth?

The market values Cross Country Healthcare Inc at about $429M (market capitalisation, as of Sep 24, 2026). Per share that is $13.25; our models calculate a fair value of $15.21 per share.

What do the bullish and bearish scenarios say about CCRN?

Our models span a range for Cross Country Healthcare Inc: cautious scenario $10.19, base $15.21, optimistic $21.23 per share (as of Sep 24, 2026, price $13.25). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of CCRN?

The PEG ratio of Cross Country Healthcare Inc is 12.54 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Cross Country Healthcare Inc (CCRN)?

Balance-sheet figures for Cross Country Healthcare Inc (as of Sep 24, 2026): return on equity −27.0%, debt of 0.46 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.

How far is CCRN from its 52-week high?

Cross Country Healthcare Inc trades at $13.25, about 7% below its 52-week high of $14.23 and 76% above the low of $7.53 (as of Jul 24, 2026). Distance from the high says nothing about value: that is what the fair value of $15.21 is for.

Which stocks are comparable to Cross Country Healthcare Inc?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Cross Country Healthcare Inc stock attractive at the current price?

The data as of Sep 24, 2026: price $13.25, calculated fair value $15.21 (+15%), Quality Score 61/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CCRN calculated?

We run Cross Country Healthcare Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $15.21, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Cross Country Healthcare Inc currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Cross Country Healthcare Inc (CCRN)?

The latest price we hold is from Jul 24, 2026 and stands at $13.25. Our model-based fair value is $15.21, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Cross Country Healthcare Inc right now?

A fairly wide model range ($10.19 to $21.23) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Cross Country Healthcare Inc

How large is the market capitalisation of Cross Country Healthcare Inc (CCRN)?

The market capitalisation of Cross Country Healthcare Inc is $429M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Cross Country Healthcare Inc (CCRN)?

The price-to-sales ratio of Cross Country Healthcare Inc is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Cross Country Healthcare Inc (CCRN)?

Earnings per share at Cross Country Healthcare Inc are $−3.05. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Cross Country Healthcare Inc (CCRN)?

The net margin of Cross Country Healthcare Inc is −9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Cross Country Healthcare Inc (CCRN)?

The return on equity (ROE) of Cross Country Healthcare Inc is −27.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Cross Country Healthcare Inc (CCRN)?

On an EBIT basis the return on assets of Cross Country Healthcare Inc is 12.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Cross Country Healthcare Inc (CCRN)?

The operating margin of Cross Country Healthcare Inc is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Cross Country Healthcare Inc (CCRN)?

Revenue at Cross Country Healthcare Inc is growing −17.8% versus a year earlier (3y avg −27.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Cross Country Healthcare Inc (CCRN)?

Earnings per share at Cross Country Healthcare Inc are growing −78.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Cross Country Healthcare Inc (CCRN) hold?

Cross Country Healthcare Inc holds more cash than debt, $106M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Cross Country Healthcare Inc in the live analysis

One click puts Cross Country Healthcare Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.